# To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes

> **NCT07539259** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University College, London** · enrollment: 445 (estimated)

## Conditions studied

- Aortic Stenosis

## Interventions

- **DRUG:** Dapagliflozin (DAPA)
- **DRUG:** Spironolactone (drug)
- **DRUG:** Spironolactone + Dapagliflozin
- **DRUG:** Epleronone

## Key facts

- **NCT ID:** NCT07539259
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2029-08
- **Final completion:** 2030-02-28
- **Target enrollment:** 445 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07539259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07539259, "To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07539259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*